Inventor · disambiguated record
Nicholas C. Flytzanis
Also filed as: FLYTZANIS NICHOLAS C
2 granted patents·9 pending applications·10 citations·filing 2019–2024
55Inventor score
Top patents by PatentIndex Score
11 records- 0189US11149256B2Adeno-associated virus compositions for targeted gene therapyCALIFORNIA INST OF TECHN·Filed 2019·Granted Oct 19, 2021·9 cites·25 claims
- 0286US12049648B2Adeno-associated virus compositions for targeted gene therapyCALIFORNIA INST OF TECHN·Filed 2021·Granted Jul 30, 2024·1 cites·19 claims
- 0378US2025179441A1Adeno-associated virus compositions for targeted gene therapyCALIFORNIA INST OF TECHN·Filed 2024·Application pending·0 cites
- 0456US2025255989A1Adeno-associated virus compositions having increased brain enrichment and/or heart enrichmentCAPSIDA INC·Filed 2023·Application pending·0 cites
- 0556US2025249124A1Adeno-associated virus compositions having increased brain enrichmentCAPSIDA INC·Filed 2023·Application pending·0 cites
- 0655US2025188128A1Adeno-associated virus compositions having increased heart enrichmentCAPSIDA INC·Filed 2023·Application pending·0 cites
- 0753US2025346637A1Adeno-associated virus compositions having increased brain enrichment and decreased liver enrichmentCAPSIDA INC·Filed 2023·Application pending·0 cites
- 0851US2025082779A1Adeno-associated virus compositions having increased brain enrichmentCAPSIDA INC·Filed 2022·Application pending·0 cites
- 0951US2025281643A1Selected aav compositions having preferred brain enrichmentCAPSIDA INC·Filed 2022·Application pending·0 cites
- 1048US2024150410A1Aav compositions having high expression levels in brainCAPSIDA INC·Filed 2022·Application pending·0 cites
- 1146US2023303630A1Adeno-associated virus compositions having preferred expression levelsCAPSIDA INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Nicholas C. Flytzanis files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →